Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apalutamide and Cytoreductive Therapy in mCSPC (CHAMPION)
NCT05717582Phase 2Not yet recruiting
- Sponsor
- Fudan University
- Start
- May 2023
- Primary completion
- Dec 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of apalutamide in prostate cancer (PCa), sponsored by Fudan University. Primary endpoint: Proportion of patients with undetectable PSA level after 6 cycles of treatment at 24 weeks. Planned start May 2023; status: not yet recruiting.
02
Drugs
apalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05717582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05717582.